azd7687
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01046357)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DGAT1 proteinINHIBITOR
Q9BRH5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd7687
- azd7687
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01217905 | Phase 1 | Nov 1, 2010 | AstraZeneca, Richmond Pharmacology |
| NCT01119352 | Phase 1 | Apr 1, 2010 | AstraZeneca, IQVIA |
| NCT01046357 | Phase 1 | Nov 1, 2009 | AstraZeneca |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2009 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1